HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $12 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Anixa Biosciences (NASDAQ:ANIX) and maintained a $12 price target.
August 29, 2023 | 10:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anixa Biosciences (NASDAQ:ANIX) has had its 'Buy' rating reiterated by HC Wainwright & Co. with a maintained price target of $12.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for Anixa Biosciences. The maintained price target of $12 also indicates the firm's continued confidence in the company's potential. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100